FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2114080253> ?p ?o ?g. }

• W2114080253 endingPage "531" @default.
• W2114080253 startingPage "525" @default.
• W2114080253 abstract "Trastuzumab is associated with improvements in overall survival (OS) among patients with HER2-positive metastatic breast cancer (MBC); however disease course and patterns of care in individual patients are highly variable.113 HER2-positive patients diagnosed with MBC from 1999 to 2005 who received trastuzumab-based therapy were retrospectively identified to allow for a minimum of 5 years of follow-up time. Median OS and median duration of therapy were determined using Kaplan-Meier methodology and group comparisons were based on the log-rank test. Hazard ratios (HR) were obtained using a Cox proportional hazards model.Median OS was 3.5 years (95% CI 3.0-4.4) from time of initiation of first therapy in the metastatic setting. On univariate analysis, central nervous system (CNS) disease at first recurrence was associated with a shorter OS compared with liver and/or lung metastases or other sites (CNS: 1.9 years CI 0.1-5.9, liver/lung: 3.2 years CI 2.5-4.2, other: 4.6 years CI 2.7-8.0; p = 0.05), however, this was not predictive of survival outcome in multivariate analysis. CNS metastases developed in 62 (55%) patients by the time of death or last follow-up. Median duration of therapy was similar up to 6 lines of treatment, and ranged from 5.2 months to 7.2 months.The natural history of HER2-positive MBC has evolved with trastuzumab-based therapy with median OS now exceeding 3 years. CNS disease is a major problem with continued risk of CNS progression over time. Patients demonstrate clinical benefit to multiple lines of HER2-directed therapy." @default.
• W2114080253 created "2016-06-24" @default.
• W2114080253 creator A5017397430 @default.
• W2114080253 creator A5037127104 @default.
• W2114080253 creator A5040999127 @default.
• W2114080253 creator A5049174232 @default.
• W2114080253 creator A5055301443 @default.
• W2114080253 creator A5070245248 @default.
• W2114080253 creator A5087875043 @default.
• W2114080253 date "2013-08-01" @default.
• W2114080253 modified "2023-10-10" @default.
• W2114080253 title "Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era" @default.
• W2114080253 cites W1836239578 @default.
• W2114080253 cites W1967930333 @default.
• W2114080253 cites W1984573641 @default.
• W2114080253 cites W1994339903 @default.
• W2114080253 cites W2013669698 @default.
• W2114080253 cites W2019607817 @default.
• W2114080253 cites W2039385294 @default.
• W2114080253 cites W2040584772 @default.
• W2114080253 cites W2051989799 @default.
• W2114080253 cites W2101824720 @default.
• W2114080253 cites W2109284739 @default.
• W2114080253 cites W2110444464 @default.
• W2114080253 cites W2117566986 @default.
• W2114080253 cites W2130521606 @default.
• W2114080253 cites W2137086207 @default.
• W2114080253 cites W2141546964 @default.
• W2114080253 cites W2149773268 @default.
• W2114080253 cites W2154246971 @default.
• W2114080253 cites W2159459001 @default.
• W2114080253 cites W2164078400 @default.
• W2114080253 cites W2165819904 @default.
• W2114080253 cites W2165824128 @default.
• W2114080253 cites W2167660860 @default.
• W2114080253 cites W2168167705 @default.
• W2114080253 cites W2171538667 @default.
• W2114080253 cites W2318605753 @default.
• W2114080253 cites W4239989216 @default.
• W2114080253 doi "https://doi.org/10.1016/j.breast.2012.12.006" @default.
• W2114080253 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3713786" @default.
• W2114080253 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23352568" @default.
• W2114080253 hasPublicationYear "2013" @default.
• W2114080253 type Work @default.
• W2114080253 sameAs 2114080253 @default.
• W2114080253 citedByCount "102" @default.
• W2114080253 countsByYear W21140802532013 @default.
• W2114080253 countsByYear W21140802532014 @default.
• W2114080253 countsByYear W21140802532015 @default.
• W2114080253 countsByYear W21140802532016 @default.
• W2114080253 countsByYear W21140802532017 @default.
• W2114080253 countsByYear W21140802532018 @default.
• W2114080253 countsByYear W21140802532019 @default.
• W2114080253 countsByYear W21140802532020 @default.
• W2114080253 countsByYear W21140802532021 @default.
• W2114080253 countsByYear W21140802532022 @default.
• W2114080253 countsByYear W21140802532023 @default.
• W2114080253 crossrefType "journal-article" @default.
• W2114080253 hasAuthorship W2114080253A5017397430 @default.
• W2114080253 hasAuthorship W2114080253A5037127104 @default.
• W2114080253 hasAuthorship W2114080253A5040999127 @default.
• W2114080253 hasAuthorship W2114080253A5049174232 @default.
• W2114080253 hasAuthorship W2114080253A5055301443 @default.
• W2114080253 hasAuthorship W2114080253A5070245248 @default.
• W2114080253 hasAuthorship W2114080253A5087875043 @default.
• W2114080253 hasBestOaLocation W21140802532 @default.
• W2114080253 hasConcept C10515644 @default.
• W2114080253 hasConcept C121608353 @default.
• W2114080253 hasConcept C126322002 @default.
• W2114080253 hasConcept C141071460 @default.
• W2114080253 hasConcept C143998085 @default.
• W2114080253 hasConcept C144301174 @default.
• W2114080253 hasConcept C207103383 @default.
• W2114080253 hasConcept C2775930923 @default.
• W2114080253 hasConcept C2779786085 @default.
• W2114080253 hasConcept C38180746 @default.
• W2114080253 hasConcept C44249647 @default.
• W2114080253 hasConcept C50382708 @default.
• W2114080253 hasConcept C509974204 @default.
• W2114080253 hasConcept C530470458 @default.
• W2114080253 hasConcept C71924100 @default.
• W2114080253 hasConceptScore W2114080253C10515644 @default.
• W2114080253 hasConceptScore W2114080253C121608353 @default.
• W2114080253 hasConceptScore W2114080253C126322002 @default.
• W2114080253 hasConceptScore W2114080253C141071460 @default.
• W2114080253 hasConceptScore W2114080253C143998085 @default.
• W2114080253 hasConceptScore W2114080253C144301174 @default.
• W2114080253 hasConceptScore W2114080253C207103383 @default.
• W2114080253 hasConceptScore W2114080253C2775930923 @default.
• W2114080253 hasConceptScore W2114080253C2779786085 @default.
• W2114080253 hasConceptScore W2114080253C38180746 @default.
• W2114080253 hasConceptScore W2114080253C44249647 @default.
• W2114080253 hasConceptScore W2114080253C50382708 @default.
• W2114080253 hasConceptScore W2114080253C509974204 @default.
• W2114080253 hasConceptScore W2114080253C530470458 @default.
• W2114080253 hasConceptScore W2114080253C71924100 @default.
• W2114080253 hasFunder F4320337351 @default.
• W2114080253 hasIssue "4" @default.

• next